[Pneumococcal infections: penicillin resistance and therapeutic implications].
Kamoun
A
A
Laboratoire de Microbiologie, Hôpital Charles Nicolle, Tunis, Tunisie.
Ben Hassen
A
A
Mahjoubi
F
F
Ben Redjeb
S
S
D000658:Amoxicillin / Q000627:therapeutic use; D000668:Ampicillin Resistance; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000627:therapeutic use; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D010347:Patient Care Planning; D010400:Penicillin G / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D010996:Pleural Effusion / Q000188:drug therapy / Q000382:microbiology; D011008:Pneumococcal Infections / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013753:Tetracycline Resistance; D013845:Thienamycins / Q000627:therapeutic use; D014133:Tracheal Diseases / Q000188:drug therapy / Q000382:microbiology; D018440:beta-Lactam Resistance
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D013845:Thienamycins; D004917:Erythromycin; D015378:Imipenem; D000658:Amoxicillin; D002439:Cefotaxime; D010400:Penicillin G
Infections à pneumocoque: résistance à la pénicilline et implications thérapeutiques.